NasdaqCM USD

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

42.99 -0.75 (-1.71%)
At close: May 10 at 4:00 PM EDT
41.51 -1.48 (-3.44%)
After hours: May 10 at 6:32 PM EDT
Loading Chart for CRBP
DELL
  • Previous Close 43.74
  • Open 43.65
  • Bid 42.52 x 100
  • Ask 43.06 x 200
  • Day's Range 40.51 - 43.88
  • 52 Week Range 3.03 - 49.87
  • Volume 92,145
  • Avg. Volume 288,904
  • Market Cap (intraday) 451.705M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -10.31
  • Earnings Date Aug 6, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 68.00

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

www.corbuspharma.com

19

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CRBP

Performance Overview: CRBP

Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CRBP
611.76%
S&P 500
9.49%

1-Year Return

CRBP
384.67%
S&P 500
26.79%

3-Year Return

CRBP
13.15%
S&P 500
23.39%

5-Year Return

CRBP
79.35%
S&P 500
81.93%

Compare To: CRBP

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CRBP

Valuation Measures

Annual
As of 5/10/2024
  • Market Cap

    451.71M

  • Enterprise Value

    451.68M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.49k

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.36%

  • Return on Equity (ttm)

    -59.52%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -33.76M

  • Diluted EPS (ttm)

    -10.31

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    120.1M

  • Total Debt/Equity (mrq)

    17.83%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: CRBP

Company Insights: CRBP

Research Reports: CRBP

People Also Watch